about
Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolinesPyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activityIdentification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based designStructure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolinesTricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agentsMutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action.Aminoglycoside resistance genes aph(2")-Ib and aac(6')-Im detected together in strains of both Escherichia coli and Enterococcus faecium.Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus.Amicoumacin a inhibits translation by stabilizing mRNA interaction with the ribosomeTranscriptional profiling and drug discovery.Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis.Identifying the targets of aminoacyl-tRNA synthetase inhibitors by primer extension inhibition.The oxazolidinones: past, present, and future.Tedizolid for the management of human infections: in vitro characteristics.Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.Analysis of the aac(3)-VIa gene encoding a novel 3-N-acetyltransferase.Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates.A novel family of Escherichia coli toxin-antitoxin gene pairs.In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents.Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.In vitro and in vivo Evaluation of the Antifungal Activity of APX001A/APX001 Against Candida auris.Analysis of beta-glucans and chitin in a Saccharomyces cerevisiae cell wall mutant using high-performance liquid chromatography.Determination of aminoglycoside resistance mechanisms of Enterobacteriaceae isolated from a hospital in Hong Kong with antibiogram and genotyping.Regulated secretion of MuGM-CSF in Saccharomyces cerevisiae via GAL1:MF alpha 1 prepro sequencesNovel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysisTetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strainsSimultaneous analysis of host and pathogen interactions during an in vivo infection reveals local induction of host acute phase response proteins, a novel bacterial stress response, and evidence of a host-imposed metal ion limited environment
P50
Q27671663-F3E911CE-4560-43E2-88E6-D06978570117Q27683826-BC744768-9E40-4350-877C-A2AC1677C4B1Q27683858-C522FA16-0B43-4C54-981C-DC692EEB95B0Q27688901-4CFF4760-EF65-4C9E-B534-1F3529A81B07Q28538023-50173FBF-3FC3-4D94-B3B3-E9519A0DC894Q33978991-0DBFF293-8AF8-40DD-BCD6-BE2710C66CA0Q33983032-4F846874-7F97-4DCF-9B32-C635F1CD9E34Q34098134-D47EC0E7-CCB3-4705-8508-F622D9B94D9DQ34617861-8050F2FA-BE0D-4354-A856-4A758C5CF465Q35559663-AE05C20F-3B8C-4F49-A131-BB7DAD802E74Q35759041-D814A259-7E99-4AF4-A097-305786BD8EC6Q37080420-DD403B04-4A92-48CA-9760-93E8425A825CQ37970719-439CFE7D-7FBD-47AD-95C1-0C354AF38A7CQ38171762-F01621B1-E981-47F4-BE72-278AB1457D1AQ39537223-C786833A-25B6-4A89-ACFF-7C726732DDE3Q39881909-43E3001B-A75A-4B2E-ACA0-03236C47D33AQ40087945-93A7258A-4A3B-46A5-8C93-80857D8BEDAAQ40171017-F2C1DD9A-38C3-40F8-A67F-36E4499384B9Q41389487-0F94295A-07D6-4EA6-9B15-0A1F79880169Q41609751-BC81CD66-5071-4D26-A310-FFE9D32D0086Q41862729-CD60D118-D88C-46FF-B962-BA69FFE463E0Q41897387-EAFE89E3-34B3-48F3-A579-FE09B5C1F762Q42024058-EABE3150-B8FD-4637-95DF-0C543BD6FC46Q43045759-9C6EB393-9EBF-47C1-8E3E-13673275E40EQ44433686-ABA99E16-7A1D-4E32-9CE9-3C0138888DB4Q45207323-92BE8799-0112-4D4D-ADD9-C701924328E3Q47195606-DF40C8C3-2632-418E-8BEF-3E3E2070DCF1Q52512873-ACE82076-6939-4EBA-A80C-EC6221AD1FF4Q54251192-C10FFF56-4AC6-4EF2-A1A3-8E719A070FF3Q68133768-5061B5AA-D475-4AEE-84F4-BBB250AE4ADCQ79973060-75C9171D-5B23-43CF-959C-D0DD1C5C034FQ80028550-27FE8C02-42BD-49A6-9160-66B119A692AAQ80377187-0B4D25F5-954C-429D-BD42-C4DCB3425463
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karen J Shaw
@ast
Karen J Shaw
@en
Karen J Shaw
@es
Karen J Shaw
@nl
type
label
Karen J Shaw
@ast
Karen J Shaw
@en
Karen J Shaw
@es
Karen J Shaw
@nl
prefLabel
Karen J Shaw
@ast
Karen J Shaw
@en
Karen J Shaw
@es
Karen J Shaw
@nl
P106
P1153
7202206453
P21
P31
P496
0000-0003-3060-1328